Valley Grande Manor: Psychotropic Drug Violations - TX
That is what inspectors found at Valley Grande Manor, a nursing home at 1212 South Bridge Street in Weslaco, when they arrived on January 30, 2026, following a complaint. At the center of what they documented was a single resident, identified in inspection records only as Resident 1, an elderly man with both Alzheimer's disease and vascular dementia who had been admitted to the facility on a date redacted from public records. His score on the Brief Interview for Mental Status, a standardized cognition screening used in nursing home assessments, was a 3. The scale runs from 0 to 15. A score of 3 indicates severely impaired cognition. He could not advocate for himself. He could not evaluate his own medications. He could not tell anyone what the drug was doing to him.
He was receiving Olanzapine, the antipsychotic sold under the brand name Zyprexa, twice a day, every day, 10 milligrams per dose, 20 milligrams total daily. The physician's order for it was dated January 1, 2026. The listed reason was Alzheimer's disease, unspecified. The order carried no end date.
The facility's pharmacist was direct when inspectors called on the afternoon of January 30. Alzheimer's disease, the pharmacist said, was not an appropriate diagnosis to justify an antipsychotic. Then the pharmacist said something more stark: an antipsychotic given to a resident with Alzheimer's disease could cause death.
That same evening, at 6:02 p.m., the facility's Assistant Director of Nursing said the same thing. The negative outcome of ordering an antipsychotic for Alzheimer's disease, the ADON told inspectors, could be death. That was why it was not recommended for residents with Alzheimer's or dementia.
Less than two hours later, the Director of Nursing sat down with inspectors and pulled up Resident 1's record on her computer. She read the Olanzapine order aloud. Then she offered an explanation: the indication of Alzheimer's disease was acceptable, she said, because Resident 1 had arrived at Valley Grande Manor with that order already written, transferred from a hospital.
The order came from the hospital. So the facility kept filling it, shift after shift, without establishing whether the diagnosis listed on it justified the drug, without documenting a behavioral symptom that the medication was meant to address, and without an end date that would have required anyone to stop and reconsider.
Inspectors reviewed Resident 1's care plan, dated January 1, 2026. It noted that he used antipsychotic medications related to Alzheimer's disease. The interventions listed were to monitor for side effects every shift and to document and report any adverse reactions. His medication administration record showed Olanzapine was given from December 31, 2025, through at least early January 2026. Side effect monitoring and behavior monitoring for the drug were both noted as beginning December 31, 2025.
What the records did not show was the thing that would have made the prescription defensible under any standard of care: a documented behavioral symptom, a specific psychiatric condition, evidence that non-drug interventions had been tried and failed, or a clinical rationale connecting this particular man's presentation to this particular drug at this dose. The facility's own antipsychotic medication policy, last revised in December 2016, stated that antipsychotic medications could be considered for residents with dementia only after medical, physical, functional, psychological, emotional, psychiatric, social, and environmental causes of behavioral symptoms had been identified and addressed. There was no documentation that any of that had happened.
The use of antipsychotic drugs in elderly patients with dementia carries a black box warning from the Food and Drug Administration, the most serious warning the agency issues. Clinical trials have shown that elderly patients with dementia-related psychosis who are treated with antipsychotic drugs die at a higher rate than those given a placebo. The causes include heart failure, sudden cardiac death, and infection. Valley Grande Manor's own pharmacist and its own assistant director of nursing described this risk to inspectors without being asked to elaborate. They knew.
What makes the inspection record particularly difficult to read past is the gap between what the staff knew and what the staff did. The ADON knew the drug could cause death in a dementia patient. The pharmacist knew Alzheimer's disease alone was not a valid indication. The DON knew the order had come from a hospital, which she appeared to treat as sufficient justification to keep administering a drug that two of her colleagues had just told a federal inspector was potentially lethal for this population. None of that knowledge had produced a medication review, a physician callback, a documented reconsideration, or a stopped order.
Resident 1 had a BIMS score of 3. He had Alzheimer's disease and vascular dementia. He was, by every clinical and legal definition, among the most vulnerable people in that building. The population of residents most at risk from inappropriate antipsychotic use is also the population least able to report dizziness, sedation, difficulty swallowing, cardiac symptoms, or any of the other effects the nurses were supposed to be monitoring for every shift. Monitoring for side effects in a man with severely impaired cognition is not the same as detecting them.
The inspection classified the deficiency as a chemical restraint violation, citing the facility's failure to ensure residents were free from medications not required to treat actual medical symptoms. The level of harm was assessed as minimal harm or potential for actual harm, a designation that reflects the absence of documented injury at the time of inspection, not an assessment of the drug's risk profile in this patient.
The DON's explanation that the order came from the hospital was, in one sense, accurate. In another sense, it described exactly the failure inspectors came to document. A nursing home that receives a transfer order and fills it indefinitely, without clinical review, without a valid indication, without an end date, and without the behavioral documentation that its own policy requires, is not following a hospital's lead. It is abandoning the independent clinical judgment that federal oversight of nursing homes exists to protect.
Resident 1 was still a patient at Valley Grande Manor as of the inspection date. The order for Olanzapine, as documented in the inspection record, had no end date.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Valley Grande Manor from 2026-01-30 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: August 4, 2026 · Our methodology
Valley Grande Manor in Weslaco, TX was cited for violations during a health inspection on January 30, 2026.
His score on the Brief Interview for Mental Status, a standardized cognition screening used in nursing home assessments, was a 3.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.